A disciplined path from innovation to medical adoption.
4th State Medical intends to pursue the regulatory pathways appropriate to each product, intended use, and market — including 510(k), De Novo, or other pathways as regulatory analysis supports.
Fourteen milestones on the regulatory pathway.
- 01Scientific and Market Assessment
Landscape review, unmet need analysis, and scientific rationale.
- 02Product Definition and Intended Use
Precise articulation of intended use and target user needs.
- 03Regulatory Classification Strategy
Analysis of applicable classification and pathway options.
- 04Quality-System Development
Establishing procedures aligned with applicable QMS expectations.
- 05Design Controls and Risk Management
Structured design inputs, outputs, verification, and risk analysis.
- 06Engineering Verification
Verification of design outputs against defined requirements.
- 07Performance and Safety Testing
Bench testing across representative use conditions.
- 08Biocompatibility Where Applicable
Evaluation aligned with applicable standards for patient-contacting elements.
- 09Electrical and Software Testing Where Applicable
Assessment aligned with recognized standards for connected systems.
- 10Human-Factors and Usability
Formative and summative evaluation of user interaction.
- 11Preclinical and Clinical Evidence Where Required
Study design and execution as needed for the intended pathway.
- 12FDA Submission
Preparation and submission of appropriate regulatory dossier.
- 13Clearance or Authorization
Response to agency review and issuance of applicable authorization.
- 14Post-Market Quality and Evidence
Surveillance, quality monitoring, and continued evidence generation.
The submission and coding path for market-facing products.
Products advanced to submission follow a coordinated regulatory-and-coding sequence intended to enable clinical adoption alongside clearance.
Characterization, biocompatibility, and process controls assembled to support submission.
Structured engagement with FDA to align on classification, testing, and evidence expectations.
Traditional or Special 510(k) demonstrating substantial equivalence to a predicate device.
Coordinated coding-and-coverage work to enable clinical adoption and reimbursement.
Full pre-market approval pursued for products where classification and evidence require it.
Response to agency review and issuance of applicable authorization prior to market entry.
A safe, advanced treatment with potential for accelerated wound and burn healing — especially in complex cases such as diabetic ulcers and trauma recovery — pending clearance and appropriate labeling.